Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2022


	March 31,		December 31,
	2022		2021
Accrued compensation	$	236,851	$	532,678
Accrued interest on preferred members’ interests		188,085		188,085
Accrued clinical research costs		1,021,220		138,522
Accrued director fees		46,500		31,000
Accrued professional fees		41,350		24,100
Other miscellaneous accrued expenses		12,500		7,375
	$	1,546,506	$	921,760